Clinical evaluation of molecular detection for sentinel lymph node examination in breast cancer patients

Clinical evaluation of molecular detection for sentinel lymph node examination in breast cancer patients - Sentinel lymph node examination by means of the OSNA method

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005321

Enrollment

450

Registered

2011-04-01

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary breast cancer

Interventions

Axillary dissection is omitted for patients who have no sentinel node metastasis examined by means of the OSNA assay.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Clinical N0 primary breast cancer patients who undergo sentinel lymph node biopsy

Exclusion criteria

Exclusion criteria: Patients without their consent. Patients who underwent primary systemic chemotherapy or primasy systemic hormonal therapy before sentinel lymph node biopsy.

Design outcomes

Primary

Measure	Time frame
Comparison of sensitivity for detection of metastasis between the OSNA assay and conventional pathology	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026